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DOI 10.1016/j.ccr.2011.04.016SUMMARYTumor inflammation promotes angiogenesis, immunosuppression, and tumor growth, but the mechanisms
controlling inflammatory cell recruitment to tumors are not well understood. We found that a range of chemo-
attractants activating G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs) and Toll-like/
IL-1 receptors (TLR/IL1Rs) unexpectedly initiate tumor inflammation by activating the PI3-kinase isoform
p110g in Gr1+CD11b+ myeloid cells. Whereas GPCRs activate p110g in a Ras/p101-dependent manner,
RTKs and TLR/IL1Rs directly activate p110g in a Ras/p87-dependent manner. Once activated, p110g
promotes inside-out activation of a single integrin, a4b1, causing myeloid cell invasion into tumors. Pharma-
cological or genetic blockade of p110g suppressed inflammation, growth, and metastasis of implanted and
spontaneous tumors, revealing an important therapeutic target in oncology.INTRODUCTION
Cancer and inflammation are intricately linked, as chronic inflam-
matory diseases such as Crohn’s disease and Barrett’s esoph-
agus increase the risk of developing tumors (Grivennikov et al.,
2010). Tumors induce host inflammatory responses that stimu-
late angiogenesis (De Palma et al., 2005; Du et al., 2008; Grune-
wald et al., 2006; Lin et al., 2006; Shojaei et al., 2007) immuno-
suppression (Bronte et al., 2000; Bunt et al., 2006; DeNardo
et al., 2010; Gabrilovich and Nagaraj, 2009; Yang et al., 2004),
and tumormetastasis (Kim et al., 2009). Neutrophils, monocytes,Significance
As inflammation stimulates tumor angiogenesis, immunosupp
are recruited to the tumor microenvironment could lead to addi
derived chemoattractants stimulating myeloid cell RTKs, TL
p110g, and a single integrin, a4b1, to promote myeloid cell
p110g is unexpectedly activated by RTKs and TLR/IL1Rs via R
only by GPCRs. Our studies reveal that PI3Kg is a single conve
Selective inhibitors of p110g could thus serve as therapeutics t
promoting tumor inflammation.and myeloid derived suppressor cells invade the tumor microen-
vironment in response to diverse tumor-derived chemoattrac-
tants, including chemokines, cytokines, and growth factors.
Myeloid cells may differentiate into tumor-associated macro-
phages (TAMs) or tumor-associated neutrophils (TANs), which
express proangiogenic and immunosuppressive factors, thereby
promoting tumor growth (Biswas and Mantovani, 2010; Frid-
lender et al., 2009; Lazennec and Richmond, 2010; Yang et al.,
2010) and relapse after therapy (Ferrara, 2010). Thus, targeting
tumor inflammation could provide substantial therapeutic benefit
to cancer patients. However, effective suppression of tumorression, and growth, understanding how inflammatory cells
tional avenues for tumor therapy. We discovered that tumor-
R/IL1Rs, and GPCRs activate a single PI3-kinase isoform,
recruitment to tumors and tumor progression. Myeloid cell
as and p87, refuting current dogma that p110g is activated
rgent point controlling tumor inflammation and progression.
o suppress tumor malignancy by blocking diverse pathways
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Figure 1. Diverse Tumor-Derived Chemoat-
tractants Promote Myeloid Cell Trafficking
to Tumors
(A) Left, CD11b+ pixels/field in normal human and
murine breast and invasive ductal breast carci-
noma, normal mouse pancreas and orthotopic
Panc02 pancreatic carcinoma, and normal murine
lung and orthotopic LLC (n = 6-10), *p < 0.001
versus normal tissue. Right, CD11b+ cells (red,
arrowheads) and nuclei (blue) in normal murine and
human breast and invasive ductal carcinoma;
scale bars, 40 mm.
(B) Graphs, quantification of myeloid (CD11b) and
endothelial (CD31) cells over time in LLC tumors,
*p < 0.05 (n = 10). Images, LLC tumor sections
immunostained to detect myeloid (CD11b) and
endothelial (CD31) cells; scale bars, 40 mm.
(C) Flow cytometric quantification of Gr1+CD11b
myeloid cells in tumors (n = 3). Tumor-derived
myeloid cells are comprised primarily of
Gr1lo/negCD11b+F4/80+CD14+MHCII+ monocyte/
macrophages.
(D) Percentage of CD11b+Gr1hi and CD11b+Gr1lo
cells in BM, PB, and tumors from normal and d14
LLC tumor-bearing mice.
(E) Relative levels of chemoattractant gene
expression in CD11b+ myeloid cells and CD11b-
tumor cells from 14 day orthotopic LLC tumors (n =
4), *p < 0.05 versus normal lung.
(F) SDF-1a and IL-1b protein expression in tumor-
derived CD11b+ myeloid and tumor cells from
14 day LLC tumors (n = 3), *p < 0.05.
See also Figure S1.
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PI3Kg: A Convergent Point in Tumor Inflammationinflammation could require identification and targeting of mech-
anisms common to the many inflammatory pathways that are
activated during tumor growth.
One family of signaling proteins implicated in inflammatory
responses is the Class I PI3K family. This group of kinases
comprises four catalytic subunit family members that phosphor-
ylate PtdIns (4,5)P2 on the 30 hydroxyl position of the inositol ring
to produce PtdIns (3,4,5)P3 (Vanhaesebroeck, et al., 2010).
PI(3,4,5)P3 interacts with plextrin homology and other lipid-
binding domains, promoting protein localization to membranes
and protein activation. Current models hold that the Class IA
PI3K isoforms p110a, b and d are activated downstream of
receptor tyrosine kinases (RTKs) through the engagement of
the regulatory p85 subunit by receptor phosphotyrosines
(Carpenter et al., 1993). In contrast, the Class IB isoform p110g
is activated by G protein-coupled receptors (GPCRs) via
the b-g subunits of heterotrimeric G proteins. Activated p110g
promotes chemotaxis and polarization of neutrophils in716 Cancer Cell 19, 715–727, June 14, 2011 ª2011 Elsevier Inc.response to GPCR ligands, such as che-
mokines (Sasaki et al., 2000; Li et al.,
2000, Hirsch et al., 2000).
The integrin family of adhesion proteins
also plays key roles in inflammation (Lobb
and Hemler, 1994; Rose et al., 2007; Jin
et al., 2006). Activation of integrin a4b1 by
inside-out signaling is required for lympho-
cyte extravasation (Feral et al., 2006; Roseet al., 2007). While extracellular stimuli induce conformational
changes and activation in integrins (Arnaout et al., 2005; Luque
et al., 1996), the signalingmechanisms bywhich integrins are acti-
vated are not well understood.
In the studies described here, we investigate the mechanisms
that control tumor inflammation and growth by examining the
roles of molecular signals that are commonly activated by
diverse tumor-derived chemoattractants, including ligands of
RTKs, Toll-like/IL1 receptors (TLR/IL1Rs) or GPCRs.
RESULTS
To identify pathways that regulate immune cell trafficking during
tumor inflammation, we characterized the extent and duration of
myeloid cell recruitment to human and murine tumors. CD11b+
myeloid cells extensively populated spontaneous or orthotopic
murine and human breast, pancreatic, and lung carcinomas
but not corresponding normal tissues (Figure 1A; see Figure S1A
Cancer Cell
PI3Kg: A Convergent Point in Tumor Inflammationavailable online). These cells persistently invaded growing
tumors over time until as much as 25% of a tumor’s mass was
comprised of myeloid cells (Figures 1B and 1C). Furthermore,
tumor inflammation was directly proportional to angiogenesis
throughout the growth of the tumor (Figure 1B; Figure S1B).
Tumor-associated myeloid cells, which were isolated by proteo-
lytic digestion of primary tumors and quantified by flow cytome-
try, primarily consisted of Gr1lo/negCD11b+ F4/80+ macro-
phages and a much smaller population of granulocytes
(Figure 1C). In contrast, myeloid cells in peripheral blood (PB)
and bone marrow (BM) of normal and tumor-bearing animals
were comprised primarily of Gr1hiCD11b+ granulocytes (80%)
and a smaller population of Gr1loCD11b+ monocytes (20%)
(Figure 1D). However, the absolute number of myeloid cells in
PB, BM and tumors increased progressively during tumor devel-
opment, indicating that the host inflammatory response is an
early and ongoing systemic process throughout tumor develop-
ment (Figures S1C and S1D). While both Gr1hi andGr1lo subpop-
ulations are able to enter tumorswhen adoptively transferred into
tumor-bearing mice (Figure S1E), only Gr1lo cells persist in
tumors (Figures 1C and 1D). Together, these results indicate
that macrophages are the major population of myeloid cells in
tumors and that they are recruited throughout tumor growth.
To investigate whether specific chemoattractants recruit
myeloid cells to the tumor microenvironment, we determined
which chemoattractants were commonly expressed in tumors.
Orthotopic murine Lewis lung carcinomas (LLC) (Figure S1F)
and pancreatic carcinomas (not shown) expressed increasing
levels of Sdf-1a, Vegf-A, Tnf-a, Il-1b, and Il-6 during tumor
growth. Surprisingly, tumor-derived myeloid cells were the
exclusive source of Il-1b and Il-6 in these tumors, while tumor
cells were the exclusive source of Sdf-1a (Figures 1E and 1F).
Importantly, a significant fraction of Vegf-A expressed in these
tumors was derived from myeloid cells (Figure 1E). Indeed,
previous studies have shown the important role of VEGF-A-
expressing myeloid cells in tumor angiogenesis (Du et al.,
2008). Our studies show that inflammatory factors in the tumor
microenvironment derive from both tumor and inflammatory
cells.
A Single Integrin, a4b1, Promotes Myeloid Cell
Trafficking to Tumors
Asmost tumors producemultiple chemoattractants, blockade of
individual chemoattractants may not suppress tumor inflamma-
tion. Therefore, we sought to determine whether a common
mechanism regulates myeloid cell recruitment to tumors. To
exit the blood stream in response to signals released from
diseased tissues, immune cells transiently adhere to and trans-
migrate through vascular endothelium. As immune cell extrava-
sation depends on adhesion to endothelial cell (EC) receptors
such as selectins, VCAM, or ICAM (Lobb and Hemler 1994;
Rose et al., 2007), we tested the ability of chemoattractants to
promote myeloid cell adhesion to EC in vivo and in vitro. Primary
Gr1hiCD11b+ and Gr1loCD11b+ myeloid cells isolated from BM
of either normal or tumor-bearing (Figure 2A; Figure S2A) mice
adhered strongly to ECs in vivo and in vitro after stimulation by
diverse tumor-derived chemoattractants (SDF-1a, IL-1b, IL-6,
VEGF-A, TNF-a, and LLC conditioned medium [TCM], which
primarily contains SDF-1a, VEGF-A and TGF-b).Myeloid cells express two receptors (integrins a4b1 and
aMb2) that recognize the EC surface adhesion proteins VCAM-1
and ICAM-1 (Lobb and Hemler 1994; Rose et al., 2007).
Antibody and peptide inhibitors of integrin a4b1 (Konradi et al.,
2006, but not aMb2, suppressed murine (Figure 2A; Figure S2B)
and human (Figure S2C) myeloid cell adhesion to ECs and to
recombinant VCAM-1, whereas antibody inhibitors of integrins
a5b1, avb5 and avb3 had no effect on adhesion (not shown).
Importantly, a4Y991A Gr1+CD11b+ cells isolated from mice
with an inactivating point mutation in the a4 integrin cytoplasmic
tail (Feral et al., 2006; Manevich et al., 2007) and a4/
Gr1+CD11b+ cells isolated from the BM of Tie2Cre a4loxp/loxp
mice (Scott et al., 2003), failed to adhere to ECs or VCAM-1,
while aM/ cells adhered normally to ECs and VCAM-1 but
not to ICAM-1 (Figure 2B, Figures S2D–S2G). Murine myeloid
cells in which integrin a4 expression was ablated by siRNA
also failed to adhere to EC and VCAM-1, while aM siRNA-
transfected cells adhered normally (Figure 2B; Figures S2H
and S2I). As chemoattractants had no effect on EC expression
of a4 ligands during these assays (Figure S2J), these results indi-
cate that diverse chemoattractants stimulate myeloid cell adhe-
sion by selectively increasing integrin a4b1 but not aMb2
activity.
Extracellular stimuli induce integrin conformational changes
that result in increased ligand-binding and cell adhesion,
a process that is called ‘‘integrin activation’’ (Arnaout et al.,
2005). We found that tumor-derived chemoattractants rapidly
induced myeloid cell integrin b1 conformational changes, as
measured by cell surface binding of HUTS21 (Luque et al.,
1996), an antibody that recognizes an epitope expressed only
on activated human b1 integrin (Figure 2C). These chemoattrac-
tants also rapidly stimulated the binding of VCAM-1 to myeloid
cells from wild-type (WT) but not integrin a4Y991A mice (Fig-
ure 2D). Together, these results indicate that chemokines, cyto-
kines, and growth factors that activate RTKs, TLR/IL1Rs, and
GPCRs all activate integrin a4b1, thereby promoting murine
and human myeloid cell adhesion to ECs.
To determine if integrin a4 activation is required for trafficking
of myeloid cells to tumors in vivo, we adoptively transferred
fluorescently labeled WT, a4Y991A, a4/, aM/, and a4
and aM siRNA transfected myeloid cells into LLC-bearing WT
mice. While WT, aM/ and aM siRNA transfected cells
arrested in tumors, cells with defective or ablated integrin a4b1
did not arrest (Figure 2E). These results provide evidence that
integrin a4 activation is required for trafficking and infiltration of
myeloid cells into tumors in vivo.
PI3-Kinase p110g Is Necessary and Sufficient for
Activation of Myeloid Cell Integrin a4b1
Our results show that chemoattractants stimulating structurally
diverse GPCRs, RTKs, TLR/IL1Rs, and type I cytokine receptors,
all activate myeloid cell integrin a4b1, indicating that a common
downstream signaling pathway may link these receptors. To
identify such a pathway, we evaluated inhibitors of various
signaling pathways in myeloid cell adhesion assays. Selective
inhibitors of PI3Kg (p110g) and Ras GTPases blocked myeloid
cell adhesion to endothelium, while inhibitors of other PI3K iso-
forms and signaling proteins had no effect on adhesion (Fig-
ure S3A). As we found that chemoattractant-induced adhesionCancer Cell 19, 715–727, June 14, 2011 ª2011 Elsevier Inc. 717
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Figure 2. Diverse Tumor-Derived Chemoattractants Promote Integrin a4b1-Dependent Myeloid Cell Trafficking
(A) Adhesion of stimulated myeloid cells to EC in the presence of medium (untreated), control IgG (cIgG), anti-a4, or anti-aM integrin antibody, or small molecule
inhibitor of integrin a4 (ELN476063) (n = 3), *p < 0.001 versus IgG.
(B) Adhesion to EC of stimulatedWT, a4Y991A, a4/, aM/ and integrin a4 (Itga4) or aM (Itgam) siRNA transfectedmyeloid cells (n = 3), *p < 0.001 versusWT.
(C) Left: HUTS21 antibody (activated integrin b1) binding to unstimulated, SDF-1a, IL1b, or Mn2+-stimulated human CD11b+ cells. Right: Mean fluorescence
intensity per stimulus (MFI).
(D) MFI of VCAM-1/Fc binding to stimulated WT or a4Y991A myeloid cells (n = 3), *p < 0.01 versus WT.
(E) Trafficking to LLC tumors of WT, a4Y991A, integrin a4/, integrin aM/ or a4 (itga4), aM (itgam), or nonsilencing siRNA transfectedmyeloid cells (n = 3–6),
*p < 0.001 versus WT cells.
See also Figure S2.
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PI3Kg: A Convergent Point in Tumor Inflammationto ECs is integrin a4b1-dependent, these results implied that
p110g activity is required for a4b1-mediated adhesion.
The class IB PI3K p110g is well described as a GPCR-
activated lipid kinase that promotes chemokine-stimulated
chemotaxis and polarization of neutrophils, lymphocytes and
thymocytes in vitro and in vivo (Sasaki et al., 2000; Li et al.,
2000; Hirsch et al., 2000). Importantly, mice lacking p110g
(p110g/) exhibit defects in granulocyte responses to chemo-
kines, which signal through GPCRs (Sasaki et al., 2000; Li et al.,
2000; Hirsch et al., 2000), as do p110g kinase-dead (KD) mice,
which express a K833R knockin mutation that inactivates
p110g catalytic activity without reducing its expression (Pa-
trucco et al., 2004). Previous studies have found p110g is essen-
tial for GPCR- but not RTK-mediated activation of PI3K activity
(Sasaki et al., 2000). Our observation that p110g inhibitors
blocked adhesion in response to GPCR as well as RTK ligands
was therefore unexpected. We investigated these results more
extensively using p110g specific knockout, knockin, and siRNA
knockdown methods.
We found that growth factors, interleukins and chemokines,
which are ligands for RTKs, TLR/IL-1Rs and GPCRs, promoted718 Cancer Cell 19, 715–727, June 14, 2011 ª2011 Elsevier Inc.adhesion of WT but not of p110g/ or p110gKD myeloid cells
to ECs or VCAM-1 (Figure 3A). As p110g/ and p110gKD
myeloid cells express normal levels of a4 integrin (Figure S3B),
these results indicate that p110g is necessary for integrin adhe-
sive activity. siRNA knockdown of p110gbut not other PI3K cata-
lytic subunits also suppressed adhesion to ECs or VCAM-1,
regardless of the stimulus (Figure 3B; Figure S3C). Selective
inhibitors of p110g, including TG100-115 (Figures S3D and
S3E) and AS605240 (Figure S3E) (Camps et al., 2005; Doukas
et al., 2006; Palanki et al., 2007) suppressed p110g activity (as
measured by pAkt levels) (Figure S3F) and blocked murine and
human cell adhesion to ECs or VCAM, while inhibitors of p110b
(TGX221) or p110a (PI3Kalpha) had minimal effects (Figures 3C
and 3D; Figure S3G). Furthermore, integrin a4 activation, as
detected in human cells by HUTS21 antibody (Figure S3H) and
in murine cells by VCAM-1 binding (Figure 3E), was also sup-
pressed in p110g inhibitor-treated and in p110g/ myeloid
cells. Although prior studies have indicated that only GPCR
ligands activate p110g, our results indicate that ligands for
RTKs and TLR/IL1Rs promote p110g activity and p110g-depen-
dent integrin a4b1 activation. These results indicate p110g is
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Figure 3. p110g PI3K Activity Is Necessary and Sufficient to Promote Myeloid Cell Trafficking to Tumors
(A and B) Adhesion to VCAM-1 of chemoattractant-treatedmurine myeloid cells from (A) WT, p110g/ and p110gKD/KD mice (n = 3), *p < 0.001 versusWT or (B)
WT myeloid cells transfected with nonsilencing, Pi3ka, b, g, or d siRNAs (n = 3–6), *p < 0.001 versus nonsilencing siRNA.
(C) Adhesion to VCAM-1 of stimulatedmurinemyeloid cells treatedwith TG100-115 and AS605240 (p110g inhibitors), TGX221 (p110b inhibitor), or PI3Ka2 (p110a
inhibitor). IC50TG100-115: IL-1b = 281 nM, SDF-1a = 158 nM; IC50AS605240: IL-b = 50 nM, SDF-1a = 50 nM. IC50 TGX221 and PI3Ka2 > 1 mM (n = 3).
(D) Adhesion to VCAM-1 of stimulated murine and human myeloid cells treated with TG100-115, AS605240, TGX221, or PI3Ka2, *p < 0.001 versus Ctrl.
(E) VCAM-1/Fc binding to SDF-1a or IL-1b-stimulated CD11b+ myeloid cells from WT or p110g/ mice or cells treated with 1 mM TG100-115, AS605240,
PI3Ka2, TGX221, or control (n = 3) *p < 0.01 versus control.
(F) Adhesion to VCAM-1 of unstimulated myeloid cells from WT and p110gCAAX mice (n = 3), *p < 0.01 versus WT.
(G) Number/105 LLC tumor cells of adoptively transferred, fluorescently labeled myeloid cells transfected with nonsilencing, Pi3k p110a, b, g, or d siRNAs,
myeloid cells pretreated with TG100-115, PI3Ka2, or TGX221, and myeloid cells isolated from p110g/ mice (n = 3), *p < 0.001 versus non sil. siRNA.
See also Figure S3.
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PI3Kg: A Convergent Point in Tumor Inflammationnecessary for growth factor, cytokine and chemokine-induced
integrin a4b1-mediated adhesion of myeloid cells.
Importantly, p110g is also sufficient for integrina4b1activation,
as cells from p110gCAAX mice, which express membrane-
targeted, constitutively activated p110g (Costa et al., 2007),
adhered strongly to ECs even in the absence of stimulation
(Figure 3F). Furthermore, siRNA-mediated knockdown and
selective inhibition of p110a, b, or d isoforms had no effect on
myeloid cell adhesion (Figures 3B–3D) or integrin activation
(Figure 3E; Figure S3H). Taken together, these results indicate
that p110g is necessary andsufficient for integrina4b1activation.
To determine if p110g is also required for trafficking of myeloid
cells to tumors in vivo, we adoptively transferred fluorescently
labeled WT, p110g/, p110g siRNA transfected and PI3Kg
inhibitor treatedmyeloid cells into tumor-bearingWTmice.While
WT cells arrested in tumors, cells deficient in p110g expression
or activation failed to arrest in tumors (Figure 3G). In contrast,inhibition of other PI3K isoforms had no effect on cell trafficking
to tumors (Figure 3G). Together, these data indicate that p110g is
necessary and sufficient to promote integrin a4b1-mediated
myeloid cell trafficking to tumors in vivo.
Direct Activation of p110g by RTKs and TLR/IL-1Rs
To understand why p110g but no other PI3K isoform is required
for myeloid cell adhesion in vitro and in vivo, we examined the
expression levels of various PI3K isoforms in primary murine
myeloid cells, lymphocytes and Lewis lung carcinoma cells.
Surprisingly, p110g is the major PI3K catalytic isoform ex-
pressed in primary myeloid cells, as these cells expressed at
least 73-fold more p110g than p110a, 243-fold more p110g
than p110b and 25-fold more p110g than p110d (Figures 4A
and 4B). Myeloid cells express the p110 regulatory subunits
p85, p87, and p101 (Figures S4A and S4B). In contrast, lympho-
cytes express large amounts of p110d, while LLC cells expressCancer Cell 19, 715–727, June 14, 2011 ª2011 Elsevier Inc. 719
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pressing the PI(3,4,5)P3 reporter AKT-PH-EGFP.
Primary myeloid cells were imaged live before and
after treatment with 200 ng/ml IL-1b, SDF-1a, or
VEGF-A. Results are expressed as the mean ratio
of AKT-PH-EGFP plasma membrane to cytosolic
fluorescence ±SEM, averaged over multiple
experiments. t = 0 corresponds to the time of
growth factor addition. Lower graphs: time cour-
ses of IL-1b, SDF-1a, or VEGF-A-stimulated
myeloid cell fluorescence with and without addi-
tion of the p110g selective inhibitor AS605240.
t = 0 corresponds to time of inhibitor addition.
(E) Representative WT or p110g/ primary
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reporter AKT-PH-EGFP imaged live before and
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See also Figure S4.
Cancer Cell
PI3Kg: A Convergent Point in Tumor Inflammationlarge amounts of p110a and b and little g or d (Figure 4A). Impor-
tantly, cytokines, growth factors and chemokines all rapidly
activated p110g in WT but not p110g/ primary myeloid cells,
as shown by phosphoAkt immunoblotting analysis (Figure 4C).
These results indicate that p110g is the major catalytically active
isoform in myeloid cells and that cytokines and growth factors
can activate p110g, refuting current dogma that p110g can be
activated only by GPCRs.
To determine whether growth factors and cytokines/interleu-
kins directly stimulate p110g activity in myeloid cells, we
measured p110g activation in murine cells expressing the
PI(3,4,5)P3 reporter Akt-PH-EGFP (Luo et al., 2005). IL-1b,
SDF-1a, and VEGF-A each rapidly stimulated PIP3 production
and reporter translocation to the membrane in WT but not in
p110g/ primary myeloid cells (Figures 4D and 4E) within
5–10 s after stimulation. Continued production of PtdIns(3,4,5)
P3 after stimulation by these factors was acutely dependent on720 Cancer Cell 19, 715–727, June 14, 2011 ª2011 Elsevier Inc.p110g activity, as treatment with the
p110g selective inhibitor AS605240
reversed Akt-PH-EGFP translocation to
the membrane within 5–10 s after its addi-
tion (Figures 4D and 4E). These results
indicate that chemokines, growth factors,
and cytokines all rapidly and directly stim-
ulate p110g activation in primary myeloid
cells.
To examine further whether growth
factors and cytokines directly activate
p110g, rather than indirectly through
GPCRs, we tested the effect of the GPCRsignaling inhibitor, pertussis toxin (Ptx) (Marrari et al., 2007; Suire
et al., 2006), on p110g activation and myeloid cell adhesion. Ptx
had no effect on RTK- and TLR/IL1R-mediated Akt phosphoryla-
tion (Figure 5A) or cell adhesion (Figure 5B), although it blocked
chemokine-mediated (SDF-1a and IL-8) effects. Additionally,
siRNA-mediated inhibition of Gb1 or Gg2 expression blocked
GPCR- but not RTK- or TLR/IL1R-induced cell adhesion (Fig-
ure 5C; Figure S5A). These results indicate that RTKs and TLR/
IL1Rs directly activate p110g in a GPCR-independent manner.
Previous studies have shown that PI3K isoformsbind receptors
or adaptorsat theplasmamembrane (Carpenter et al., 1993;Suire
et al., 2006; Voigt et al., 2006;Kurig et al., 2009).We reasoned that
if p110g is directly activated by growth factors, it should closely
associatewithRTKsat theplasmamembrane upon receptor acti-
vation. To test whether p110g exhibits this behavior, we immuno-
precipitated VEGFR1 (RTK) as well as CXCR4 (GPCR), the cell
surface receptors for VEGF-A and SDF-1a, respectively, from
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Figure 5. RTKs and TLR/IL-1Rs Activate
p110g Directly via p87
(A) Immunoblots of pThr308Akt and total Akt in
chemoattractant-stimulated myeloid cells treated
with or without 100 ng/ml Ptx.
(B and C) Adhesion to VCAM-1 of chemo-
attractant-stimulated myeloid cells treated (B) with
or without 100 ng/ml Ptx or (C) transfected with
nonsilencing (Non sil.), Gb1, or Gg2 siRNA (n = 3),
*p < 0.001 versus control (B) or versus non-
silencing (C).
(D) p110g coimmunoprecipitation with VEGFR1
(upper) or CXCR4 (lower) in unstimulated (basal),
VEGF-A, or SDF-1a-stimulated primary myeloid
cells.
(E) Coimmunoprecipitation of p87 or p101 with
p110g from membrane fractions of unstimulated
(basal), VEGF-A, or SDF-1a-stimulated primary
myeloid cells.
(F) Immunoblots of p110g and integrin a4 in
membrane fractions from unstimulated (basal),
SDF-1a, VEGF-A, and IL-1b-stimulated myeloid
cells transfected with nonsilencing, p87, p101, and
N/K Ras siRNAs.
(G) Adhesion to VCAM-1 of nonsilencing (Non sil.),
p87, p101, and Ras siRNA transfected myeloid
cells (n = 3), *p < 0.001 versus nonsilencing siRNA.
(H) Trafficking to tumors of myeloid cells trans-
fected with nonsilencing, p110g, p101, or p87
siRNA (n = 3). *p < 0.001 versus nonsilencing
siRNA.
See also Figure S5.
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PI3Kg: A Convergent Point in Tumor Inflammationunstimulated and VEGF-A and SDF-1a-stimulated myeloid cells.
We found that p110g, but not other p110 isoforms, coimmunopre-
cipitated with VEGFR1 upon stimulation with VEGF-A but not
SDF-1a (Figure 5D; Figure S5B). In contrast, p110g coimmuno-
precipitated with the SDF-1a receptor CXCR4 upon stimulation
with SDF-1a but not with VEGF-A (Figure 5D). Taken together,
these results support the concept that RTKs and TLRs directly
activate p110g in a GPCR-independent manner, thereby
promoting myeloid cell adhesion.
Myeloid Cell RTKs Activate p110g in a p87-Dependent
Manner
Upon stimulation by cell surface receptors, PI3K regulatory and
catalytic subunits translocate to plasma membranes, where
interactionswithGPCR-activatedGbg, tyrosine kinase receptors
or Ras relieve regulatory subunit inhibition and stimulate catalytic
activity. Chemo attractants activating GPCRs (SDF-1a), TLR/
IL-1Rs (IL-1b), and RTKs (VEGF-A) all stimulated membraneCancer Cell 19, 715–7translocation of myeloid cell p110g, but
not p110d, p110a, or p110b (Figure S5C).
p110g has been shown to associate with
either of two regulatory subunits, p101
which is activated by binding to Gbg,
and p87, which is Gbg-independent but
Ras-dependent (Suire et al., 2006; Voigt
et al., 2006; Kurig et al., 2009). We tested
the roles of p101 and p87 in the activation
of p110g by RTKs and GPCRs and foundthat the RTK ligand VEGF-A-stimulated p87 but not p101
membrane translocation and coimmunoprecipitation with
p110g, while the GPCR ligand SDF-1a induced p101 but not
p87 membrane translocation and coimmunoprecipitation with
p110g in primary myeloid cells (Figure 5E). Importantly, RTK
and TLR-dependent p110g translocation was blocked in p87
but not p101 siRNA transfected cells (Figure 5F; Figure S5D).
GPCR-dependent p110g membrane translocation was blocked
in p101- but not in p87-siRNA transfected cells, while membrane
localization induced by all stimuli was blocked by Ras siRNAs
(Figure 5F; Figure S5D). Similarly, growth factor and cytokine-
dependent cell adhesion was blocked in p87 but not p101 siRNA
transfected cells, while chemokine-dependent cell adhesionwas
blocked in p101 but not in p87 siRNA transfected cells (Fig-
ure 5G). Additionally, siRNA-mediated suppression of p87 and
p101 partially blocked myeloid cell invasion of tumors in vivo,
and siRNA-mediated suppression of both regulatory subunits
completely blocked infiltration of myeloid cells, similarly to27, June 14, 2011 ª2011 Elsevier Inc. 721
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Figure 6. Ras Is Necessary and Sufficient to Acti-
vate Myeloid Cell p110g
(A) Immunoblots of active (GTP-Ras) and total Ras in
chemoattractant-stimulated myeloid cells with or without
100 ng/ml Ptx.
(B) Adhesion to VCAM-1 of control (Non sil.), N/K Ras-,
Raf-, andMek-siRNA transfectedmyeloid cells (n = 3), *p <
0.01 versus control.
(C) Adhesion to VCAM-1 of control-, RasV12-,
RasV12C40-, and RasV12S35-transfected myeloid cells
(n = 3), *p < 0.01 versus vector control.
(D) Adhesion to VCAM-1 of RasV12 transfected cells
treated with TG100-115; p110g/ myeloid cells trans-
fected with RasV12, andWTmyeloid cells transfectedwith
RasV12 in combination with nonsilencing, p110a, p110b,
p110g, p110d, and itga4 siRNA. (n = 3), *p < 0.01 versus
RasV12. (E) VCAM-1/Fc binding (MFI) to WT or p110g/
myeloid cells transfected with RasV12 in combination with
nonsilencing, p110a, b, g, or d siRNAs (n = 3), *p < 0.01
versus WT.
(F) Trafficking to tumors of control or FTI treated myeloid
cells and control transfected (Non-Sil.) or N/K Ras siRNA
transfected myeloid cells (n = 3), *p < 0.01 versus Ctrl.
See also Figure S6.
Cancer Cell
PI3Kg: A Convergent Point in Tumor InflammationsiRNA-mediated suppression of p110g (Figure 5H). Taken
together, these findings demonstrate that in primary myeloid
cells, p110g is activated byRTKs and TLR/IL1Rs in a p87-depen-
dent manner and is activated by GPCRs in a p101-dependent
manner in vitro and in vivo. Importantly, these results indicate
that diverse chemoattractant signals converge on p110g to
promote tumor inflammation and suggest that blocking p110g
activity might be an effective strategy to suppress tumor
inflammation.
Ras Is Necessary and Sufficient to Promote
p110g-Dependent Cell Adhesion
Ras isan important regulatorofPI3Kactivity, as it enhancesp110g
activation through direct interaction with the p110g N-terminus
(Suire et al., 2006; Kurig et al., 2009; Rubio et al., 1997; Pacold
et al., 2000). In addition, the p87/p110g complexes interact with722 Cancer Cell 19, 715–727, June 14, 2011 ª2011 Elsevier Inc.Ras to promote p110g membrane translocation
and activation (Kurig et al., 2009). We found that
ligands for GPCRs, RTKs, and TLR/IL1Rs all
stimulated Ras activity, although only GPCR
ligands require heterotrimeric G proteins, as
only Ras activation induced by SDF-1a or by
IL-8 was blocked by Ptx (Figure 6A). Adhesion
stimulated by RTK, TLR/IL1R, or GPCR ligands
was blocked by a combination of N and K Ras
siRNAs but not by Raf or MEK siRNAs or inhibi-
tors (Figure 6B; FiguresS6A–S6C). Thesestudies
show that Ras is necessary for p110g activation
and myeloid cell adhesion in response to all
chemoattractants.
Ras is also sufficient for promoting p110g-
mediated integrin a4b1 activation in myeloid
cells. WT but not p110g/ cells expressing
activated RasG12V (V12Ras) exhibited consti-
tutive adhesion (Figures 6C and 6D) and ligandbinding (Figure 6E), indicating constitutive integrin activation.
Expression of V12RasS35, which cannot bind p110g, failed to
stimulate adhesion, while V12RasC40, which binds p110g but
cannot bind to the Ras substrate Raf, stimulated constitutive
adhesion (Figure 6C). Importantly, RasV12-mediated adhesion
and ligand binding were blocked in cells expressing p110g but
not a, b or d, siRNAs. Similarly, PI3Kg inhibitor (TG100-115)-
treated and p110g/ myeloid cells did not respond to
RasV12 expression (Figure 6D). Additionally, expression of full-
length p110g in p110g/ cells restored adhesion to VCAM-1,
but expression of p110g with a Ras-binding domain deletion
failed to restore adhesion in these cells (Figure S6C). RasV12-
mediated adhesion was also blocked in a4 integrin siRNA trans-
fected cells (Figure 6D). Together, these data indicate that Ras is
necessary and sufficient to activate p110g-mediated integrin
a4b1-dependent cell adhesion to VCAM-1. Finally, trafficking
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Figure 7. p110g and Integrin a4b1 Are
Required for Tumor Inflammation, Growth,
and Progression
(A) Tumor weight, percent Gr1+CD11b+ cells (filled,
Gr1lo; white, Gr1hi) in tumors, and CD31+ pixels/
field in LLC, Panc02, and B16 tumors in WT and
p110g/ mice (n = 8–10), *p < 0.01 versus WT.
(B) Immunoblot analyses of p110a and p110g in
tumor-derived CD11b+ and LLC cells.
(C) LLC tumor volume, percent Gr1+CD11b+ cells
(filled, Gr1lo; white, Gr1hi) in tumors, and circulating
WBCs/ml in WT mice with WT (black) or p110g/
bone marrow (BM, red), and in p110g/mice with
WT (blue) or p110g/ BM (green) bone marrow;
*p < 0.01 versus WT/WT.
(D) Tumor volume and percent Gr1+CD11b+ cells in
LLC tumors grown in WT (black line) and p110gKD
(red line) animals and in WT animals with WT BM
(blue) or p110gKD BM (green), (n = 9–10 per group)
*p < 0.01 versus WT.
(E) LLC or Panc02 tumor weight, percent Gr1+-
CD11b+ cells in tumor, and CD31+ pixels/field in
WT or a4Y991A (YA) animals transplanted with WT
or YA BM (n = 8) *p < 0.05 versus WT mice with
WT BM.
(F) Circulating WBCs/ml in WT mice with WT or
a4Y991A BM.
(G) Images, H&E-stained diaphragm and colon from
BM transplanted, Panc02 implanted animals from
(E), scale bars, 40 mm. Graphs, incidence of colon
and diaphragm metastases (n = 8), *p < 0.05 versus
WT/WT.
See also Figure S7 and Table S1.
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PI3Kg: A Convergent Point in Tumor Inflammationof myeloid cells to tumors was significantly suppressed in Ras
siRNA transfected and farnesyltransferase inhibitor-treated cells
(Figure 6F). Taken together with our data indicating the depen-
dence of in vivo trafficking on p110g and integrin a4b1, these
results indicate that Ras is both necessary and sufficient for acti-
vation of p110g and integrin a4 in primary myeloid cells during
tumor inflammation. Our results thus indicate that GPCR ligands
stimulate myeloid cell adhesion in a Gbg-p101/p110g-Ras-
dependent manner, while RTK and TLR/IL1R ligands stimulate
adhesion in a p87-p110g-Ras-dependent but Gbg-independent
manner.
Myeloid Cell p110g Is Required for Tumor Inflammation,
Growth, and Metastasis
To explore the role of PI3Kg in tumor inflammation and growth
in vivo, we evaluated tumor growth in animals with deleted
or catalytically inactive p110g. Tumor growth, invasion of
Gr1loCD11b+ and Gr1hiCD11b+ cells, angiogenesis and metas-Cancer Cell 19, 715–tasis were substantially suppressed in
p110g/ mice implanted with syngeneic
subcutaneous LLCs, orthotopic pancre-
atic carcinoma andmelanomas (Figure 7A;
Figures S7A–S7C). Importantly, myeloid
cells but not tumor cells expressed
p110g, while tumor cells but not myeloid
cells expressed p110a (Figure 7B). Levels
of circulating myeloid cells were identicalin normal and tumor-bearing WT and p110g/ animals (Table
S1). To determine whether tumor growth suppression resulted
from decreased myeloid cell invasion, we characterized the
growth of tumors in mice transplanted with BM from p110g/
and WT animals. BM from p110g/ and WT mice engrafted
with equal efficacy (Figure 7C; Figure S7D); recruitment of
Gr1loCD11b+ and Gr1hiCD11b+ cells and macrophages, angio-
genesis and tumor growth were significantly suppressed in mice
transplanted with p110g/ BM, but not in p110g/ or WT
mice transplanted with WT BM (Figure 7C, Figure S7E).
As p110g has been shown to exhibit kinase-independent
adaptor protein functions (Patrucco et al., 2004), we determined
if the catalytic activity of p110g is required for tumor inflamma-
tion and growth by evaluating tumor growth in p110gKD mice
and in WT mice transplanted with p110gKD BM. Although
p110gKD and WT BM engrafted equally (Figure S7F), we
observed substantial impairment of myeloid cell recruitment
and LLC tumor growth in p110gKD mice and in mice with727, June 14, 2011 ª2011 Elsevier Inc. 723
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PI3Kg: A Convergent Point in Tumor Inflammationp110gKD BM (Figure 7D). As we have observed no intrinsic
differences in the numbers of myeloid cells in peripheral blood
or BM of normal or tumor-bearing mutant and WT animals and
no defects in growth factor-induced angiogenesis in p110g/
mice (Serban et al., 2008), these studies indicate that p110g-
mediated integrin a4 activation in myeloid cells plays a key role
in tumor inflammation and growth.
In support of our findings that p110g plays a critical role in acti-
vating integrin a4b1 during tumor inflammation, we found that
the growth of subcutaneous LLC and orthotopic Panc02 tumors
were also suppressed inmice transplanted with BM from integrin
a4Y991A mice. Recruitment of Gr1+CD11b+ myeloid cells,
angiogenesis, tumor growth and spontaneous metastases
were suppressed in mice transplanted with BM expressing
a4Y991A, even though BM from a4Y991A animals and WT
mice engrafted with equal efficacy (Figures 7E–7G; Figures
S7G and S7H), Myeloid cell infiltration, neovascularization and
tumor growth were also suppressed in a4Y991A animals im-
planted with LLCs, orthotopic pancreatic carcinoma, and ortho-
topicmelanoma cells (Figure S7I), even though a4Y991A animals
exhibit normal myeloid cell levels (Table S1). These studies
demonstrate that p110g together with integrin a4 promote tumor
inflammation, which leads to tumor angiogenesis, growth, and
metastasis.
Inhibition of PI3-Kinase p110g Blocks Spontaneous
Breast Tumor Progression
Pan-PI3kinase inhibitors are currently under clinical investigation
to determine their usefulness in cancer therapy, but these agents
broadly inhibit all PI3-kinase isoforms. Becausewe observed that
all chemoattractant signals converge on p110g, we evaluated the
efficacy of two p110g inhibitors, TG100-115 and AS605240 in
tumor growth models. TG100-115 had no effect while pan-PI3
kinase inhibitors inhibited in vitro tumor cell proliferation (Fig-
ure S8A). In contrast, a single 2.5 mg/kg intravenous dose of
TG100-115 rapidly and sustainably inhibited myeloid cell p110g
catalytic activity and adhesion to VCAM-1, with inhibition lasting
approximately 12 hr (Figure S8B). We therefore treated mice
bearing LLC tumors with daily doses of 0.05, 0.5, and 5 mg/kg
TG100-115, 5 mg/kg of AS605240, or 5 mg/kg of a chemically
similar but inactive control compound (Control) for 3 weeks.
TG100-115 and AS605240 suppressed lung carcinoma inflam-
mation, angiogenesis and tumor growth, with an IC50 of
0.5 mg/kg for TG100-115 (Figure 8A; Figure S8C). TG100-115
had no direct effect on LLC tumor cell proliferation in vivo, as it
did not inhibit LLC tumor growth in p110g/ mice (Figure 8B;
Figure S8D). As p110g is not expressed in LLC tumor cells but is
mainly expressed in BM-derived cells, our studies indicate that
PI3Kg inhibitorsblock tumor growthby inhibiting tumor inflamma-
tion and angiogenesis without directly affecting tumor cells.
To determine whether myeloid cell p110g and integrin a4b1
also regulate spontaneous tumor progression, we investigated
the growth of PyMT spontaneous breast carcinomas in
p110g/ and integrin a4Y991A mice and in mice treated with
daily doses of 5 mg/kg TG100-115. Spontaneous breast carci-
noma growth was strongly inhibited in p110g/ and integrin
a4Y991A PyMTmice and in TG100-115 treatedmice (Figure 8C).
Gr1+CD11b+ myeloid cell and macrophage recruitment was
strongly reduced in mammary tumors from these mice (Fig-724 Cancer Cell 19, 715–727, June 14, 2011 ª2011 Elsevier Inc.ure 8C; Figure S8E). Additionally, the number of macrophages
in TG100-115 treated or p110g/ tumors was reduced to or
below the level of macrophages found in early hyperplastic
lesions (Figure S8E). Importantly, myeloid cells but not PyMT
tumor cells express p110g, while tumor cells but not myeloid
cells expressed p110a (Figures S8F and S8G). p110g inhibitors
had no effect on PyMT tumor cell growth in vitro (Figure S8H).
Together, these results indicate that p110g inhibitors directly
affect myeloid but not tumor cells. Tumor angiogenesis was
also suppressed in these animals (Figure 8C).
Tumor progression was strongly inhibited in p110g/,
a4991A, and TG100-115-treated animals, as tumors in these
animals exhibited substantially less carcinoma and more normal
tissue than control-treated animals (Figures 8D–8F; Table S2).
Together, these studies indicate that p110g-mediated integrin
a4 activation in myeloid cells promotes spontaneous tumor
inflammation and growth and demonstrate that p110g inhibitors
are useful in controlling spontaneous tumor growth and malig-
nancy. Importantly, we found that expression of inflammatory
and proangiogenic factors within tumors was substantially sup-
pressed in both p110g/ and a4Y991A tumors, indicating that
blockade of inflammatory cell infiltration of tumors has dramatic
impacts on the proangiogenic, proinflammatory milieu of the
tumor (Figure S8I).
In conclusion, our studies demonstrate that tumor-derived
chemokines, growth factors and cytokines promote tumor
inflammation and progression by activating p110g in inflamma-
tory cells. Surprisingly, cytokines and growth factors activate
p110g in a p87-Ras-dependent manner, while chemokines acti-
vate p110g in a Gbg-p101-Ras-dependent manner in primary
myeloid cells. Both pathways play key roles in tumor inflamma-
tion. p110g then promotes integrin a4b1 activation, with subse-
quent stimulation of myeloid cell trafficking, tumor growth and
progression (Figure 8G).
DISCUSSION
Beginning with the observation that tumor-derived chemoattrac-
tants ligands for RTKs, TLR/IL1Rs, and GPCRs promote tumor
inflammation and progression, we found that RTK and TLR/
IL1R signals can directly activate p110g in inflammatory myeloid
cells. We observed that RTKs and TLR/IL1Rs activate p110g in
a manner dependent on p87 and Ras but independent of heter-
otrimeric G proteins. In contrast, GPCRs activate p110g in
a Gbg-p101-Ras-dependent manner. Both pathways promote
a4b1 activation and myeloid cell adhesion to vascular endothe-
lium in tumors, leading to tumor angiogenesis, growth and
progression. Our studies refute current dogma that p110g can
be activated only by GPCRs, as we show that myeloid cell
p110g is directly and rapidly activated by RTKs and TLR/
IL1Rs. Our studies demonstrate that tumor inflammation and
growth are critically dependent on p110g and that selective,
small molecule inhibitors of p110g strongly suppress sponta-
neous tumor growth by blocking inflammation. Importantly, as
these observations were made in both murine and human
myeloid cells, our results indicate that selective p110g inhibitors
have good potential as cancer therapeutic agents.
We also made the surprising observation that only integrin a4
and not aMb2 or other integrins is required to promote adhesion
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Figure 8. p110g Inhibition Blocks Spontaneous Breast Tumor Growth and Progression
(A) Mice with LLC tumors were treated with control, AS605240, or TG100-115 (n = 10). Left, tumor volume, *p < 0.01 versus control. Middle, percent Gr1+CD11b+
cells, **p < 0.001 versus control. Right, CD31+ pixels/field in control (black) and 0.5 mg/kg/day TG100-115 treated (green) tumors, **p < 0.001 versus control.
(B) Tumor volume in WT (black) and p110g/ (red) mice with LLC tumors treated with control, and WT mice (green) and p110g/ mice (blue) treated with
TG100-115 at 5 mg/kg/day.
(C) Tumor burden, CD11b+ myeloid cells and CD31+ blood vessels in spontaneous breast tumors from 9-week-old control and TG100-115 treated, p110g+/+
and p110g/, and WT and a4Y991A FVB PyMT+ mice (n = 10), *p < 0.01 versus control.
(D) Whole mounts of fourth mammary glands from (C). Arrowheads, adenocarcinoma. LN, lymph node, scale bars, 400 mm.
(E) Percent area of normal, hyperplastic, and carcinoma tissue from C (n = 10), p < 0.001 carcinoma versus WT, p < 0.01 normal tissue versus WT and p = 0.45
hyperplasia versus WT.
(F) H&E-stained mammary glands from (C), scale bars, 40 mm.
(G) Role of p110g during tumor inflammation: cytokines and growth factors activate primary myeloid cell p110g in a p87-Ras-dependent manner, and
chemokines activate p110g in a Gbg-p101-Ras-dependent manner. Both pathways promote integrin a4b1 activation, with subsequent stimulation of myeloid cell
trafficking, tumor growth, and progression.
See also Figure S8 and Table S2.
Cancer Cell
PI3Kg: A Convergent Point in Tumor Inflammationof myeloid cells to tumor vascular endothelium in vivo. Although
beta2 integrins have previously been shown to mediate lympho-
cyte adhesion to ECs, our studies indicate that this integrin is not
required for myeloid cell invasion of tumors.
While we have shown that RTK, TLR/ILR and GPCR-mediated
activation of Ras and p110g promote integrin a4 activation, the
pathway by which p110g promotes integrin a4 activation is not
yet clear. The requirement for p110g kinase activity indicates
that PtdIns(3,4,5)P3 production is crucial. However, the target
of PtdIns(3,4,5)P3 that mediates integrin activation remains
unknown.The small GTPase Rap1 promotes integrin activationby inducing talin binding to integrin b chains (de Bruyn et al.,
2002; Lee et al., 2009). This event disrupts electrostatic interac-
tions between integrin a and b chains and leads to a shift in the
conformation of the extracellular domain of the integrin and
increases ligandbinding (Costaet al., 2007).Whileourpreliminary
studies indicate that p110g activates Rap1 to promote integrin
activation (not shown), it is currently unclear howPI3Kg activates
Rap1. An attractive model would be the binding of PH-domain-
containing Rap1 exchange factors to PtdIns(3,4,5)P3, effectively
activating and localizing Rap1 at the plasma membrane where it
might act on integrin a4b1 (Bergmeier et al., 2007).Cancer Cell 19, 715–727, June 14, 2011 ª2011 Elsevier Inc. 725
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PI3Kg: A Convergent Point in Tumor InflammationPI3Ks have become attractive targets for cancer therapy. Acti-
vating mutations in p110a occur frequently in human cancers,
and more generally, the RTK-Class 1A PI3K pathway (utilizing
p110a and p110b) is one of the most common targets of onco-
genic mutations. A number of clinical trials are underway testing
pan-PI3K inhibitors in cancer patients (Cleary and Shapiro,
2010). However, our studies indicate that p110g is an excellent
target for a relatively nontoxic cancer therapeutic, as this isoform
is primarily expressed by myeloid cells and is a convergence
point of diverse chemoattractant signaling pathways that are
required for tumor inflammation and tumor progression. PI3K
p110g inhibitors strongly suppressed tumor growth and progres-
sion in mice without apparent side effects. In conclusion, our
data demonstrate alternate pathways whereby tumor derived
factors that activate GPCRs, RTKs and TLRs promote PI3K
p110g to activate integrin a4b1-dependent tumor inflammation,
growth, and progression.
EXPERIMENTAL PROCEDURES
Institutional Approvals
All studies involving human tissues were approved by the University of
California, San Diego IRB and were considered exempt according to federal
guidelines. All experiments on live animals were performed in accordance
with institutional and national guidelines and regulations, under approval by
the UCSD IACUC.
Adhesion Assays
Calcein-AM labeled human or murine CD11b+ cells (1 3 105) were incubated
on human or murine EC monolayers or plastic plates coated with 5 mg/ml
recombinant soluble human or murine VCAM-1 or ICAM-1 (R&D Systems)
for 30 min at 37C in the presence of TCM or DMEM containing 200 ng/ml
SDF1a, IL-1b, IL-6, IL-8, TNF-a, C5a, CSF-1, or VEGF-A (R&D Systems). After
washing with warmed medium, adherent cells were quantified using a plate
fluorimeter (GeniosPro, TECAN).
Gene Expression
Total RNA was isolated from cells and tissues using ISOGEN (Nippon Gene).
cDNA was prepared from 1 mg RNA/sample, and qPCR was performed using
gene specific QuantiTect Primer Assay primers from QIAGEN. Relative
expression levels were normalized to gapdh expression according to the
formula < 2^- (Ct gene of interest – Ct gapdh) >. Fold increase in expression
levels were calculated by comparative Ct method < 2^- (ddCt) >.
Animal Studies
Integrin a4Y991A and p110g/ mice in C57BL6 or FVB lineages were used
for tumor studies. p110g/mice were obtained from Dr. Joseph Penninger,
Institute of Molecular Biotechnology, Vienna, Austria. p110gKD mice and
p110gCAAX mice were developed and maintained in the Hirsch lab. aMb2/
 mice were from Jackson Laboratories. Panc02, LLC, or B16 cells (5–10 3
105) were injected subcutaneously or orthotopically into syngeneic 6- to
8-week-old mice; tumors dimensions and weights were recorded regularly.
Tumors were cryopreserved in OCT, solubilized for RNA purification, or colla-
genase-digested for flow cytometric analysis of CD11b and Gr1 expression.
Angiogenesis was measured by CD31 immunostaining. All tumor experiments
were performed three to four times with n = 8–14, except those in p110gKD
mice and p110gKD BM transplanted mice were performed once (n = 10).
Quantification of AKT-PH-EGFP Translocation
Freshly isolated BM-derived murine CD11b+ cells were transfected with AKT-
PH-EGFPexpressionplasmid (Luoet al., 2005) by electroporation usingAmaxa
macrophage transfection protocols. Cells were imaged live using an Olympus
IX81-ZDC spinning disc confocal microscope controlled by Slidebook
software. Cells in suspension were seeded onto a glass bottom dish
contained within a 37C, 5% CO2 chamber above a heated 37C 603 1.4 NA726 Cancer Cell 19, 715–727, June 14, 2011 ª2011 Elsevier Inc.objective. Confocal GFP images were collected every 2 s before and after
addition of 200 ng/ml IL-1b, SDF-1a, VEGF-A, or basal media. The ratio of
plasmamembrane to cytosolic intensitywasmeasuredusing ImageJsoftware.
Statistical Methods
In vitro assay data (n = 3–5/group) were analyzed for significance using
Student’s two-tailed t test. In vivo data (n = 6–14/group) were analyzed by
one-way ANOVA, coupled with posthoc Tukey’s test for pairwise comparison.
All errors reported are SEM. All animal studies were performed two to four
times.
Additional procedures are described in Supplemental Information.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and two tables and can be found with this article online at
doi:10.1016/j.ccr.2011.04.016.
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